Table 1.
Immunohistochemistry cohort: associations between APLNR protein expression and clinicopathological parameters in clear-cell RCC (n = 253)
| Tumour vascular expression, staining intensity | Tumour cell cytoplasm expression, staining intensity | |||||||
|---|---|---|---|---|---|---|---|---|
| “0” | “1” | “2” | “3” | “0” | “1” | “2” | “3” | |
| Histological grade (WHO 2016), n (%) | ||||||||
| G1 | 1 (2.0%) | 17 (33.3%) | 17 (33.3%) | 16 (31.4%) | 7 (13.7%) | 34 (66.7%) | 8 (15.7%) | 2 (3.9%) |
| G2 | 5 (3.5%) | 45 (31.7%) | 56 (39.4%) | 36 (25.3%) | 15 (10.6%) | 73 (51.4%) | 38 (26.8%) | 16 (11.3%) |
| G3 | 3 (7.6%) | 14 (35.8%) | 14 (35.8%) | 8 (20.5%) | 1 (2.6%) | 11 (28.2%) | 17 (43.6%) | 10 (25.6%) |
| G4 | 9 (42.9%) | 9 (42.9%) | 1 (4.7%) | 2 (9.5%) | 3 (14.3%) | 8 (38.1%) | 7 (33.3%) | 3 (14.3%) |
| p-levela | 3.6e−08 | 0.002 | ||||||
| pT-stage, n (%) | ||||||||
| pT1 | 4 (2.7%) | 52 (34.9%) | 48 (32.2%) | 45 (30.2%) | 14 (9.4%) | 81 (54.4%) | 41 (27.5%) | 13 (8.7%) |
| pT2 | 3 (17.6%) | 2 (11.8%) | 10 (58.8%) | 2 (11.8%) | 0 (0%) | 7 (41.2%) | 8 (47.1%) | 2 (11.8%) |
| pT3 + pT4 | 11 (12.6%) | 31 (35.6%) | 30 (34.5%) | 15 (17.2%) | 12 (13.8%) | 38 (43.7%) | 21 (24.1%) | 16 (18.4%) |
| p-levela | 0.002 | 0.08 | ||||||
aPearson’s Chi-squared test